Kerendia (finerenone) was launched in the United States in July 2021 [1].
When can other companies start selling generic Kerendia?
The patent exclusivity for Kerendia is set to expire. According to DrugPatentWatch.com, the earliest patent expiry date for finerenone is in 2037 [2]. However, patent landscapes can be complex, involving multiple patents and potential legal challenges that could affect the timeline for generic entry.
What is Kerendia used for?
Kerendia is a medication prescribed to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, cardiovascular death, non-fatal heart attacks, and stroke in adults with chronic kidney disease (CKD) associated with type 2 diabetes [1]. It works by blocking the harmful effects of overactivation of the mineralocorticoid receptor (MR) [1].
How does Kerendia compare to other CKD treatments?
Kerendia represents a new class of medication for managing CKD in patients with type 2 diabetes. Unlike previous treatments that primarily focused on blood pressure or glucose control, Kerendia targets the underlying inflammatory and fibrotic pathways associated with MR overactivation [1]. This mechanism differentiates it from other therapies, aiming to slow kidney disease progression more directly [1].
What are the potential side effects of Kerendia?
Common side effects associated with Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [1]. Patients are advised to monitor their potassium levels regularly during treatment.
Who makes Kerendia?
Kerendia is developed and marketed by Bayer [1].